Proposal of an Integrated Patient Journey roadmap for the introduction of the first gene therapy for haemophilia B in Spain – The BHEMOGEN project

Other authors

Institut Català de la Salut

[Álvarez-Román MT, García S] La Paz University Hospital, Madrid, Spain. [Bonanad S] La Fe University and Polytechnic Hospital, Valencia, Spain. [Herrera C] Reina Sofía General University Hospital, Córdoba, Spain. [Rodríguez López M] Álvaro Cunqueiro University Hospital, Vigo, Spain. [García-Diego DA] Spanish Federation of Haemophilia (FEDHEMO), Spain. [Montoro JB] Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-05-07T07:25:57Z

2025-05-07T07:25:57Z

2025



Abstract

Gene therapy; Haemophilia B; Patient journey roadmap


Teràpia gènica; Hemofília B; Full de ruta del recorregut del pacient


Terapia genética; Hemofilia B; Hoja de ruta del recorrido del paciente


Background The approval of the first gene therapy for haemophilia B represents a disruptive innovation in its management. Its practical integration into the Spanish national healthcare system presents unique challenges and opportunities, requiring the development of a structured, coordinated and multidisciplinary patient journey roadmap to ensure high-quality patient care and outcomes measurement. Methods A multidisciplinary panel of 10 experts was established. The project involved a literature review, structured questionnaires, individual interviews, practical exercises and validation of results by focus group with nominal group methodology. Results No specific patient journey for haemophilia B or for gene therapy were identified in Spain. Associated changes required for current treatment of haemophilia B were identified and proposals made: 1) selection of candidates to receive gene therapy involves individualised assessment of eligibility criteria by a multidisciplinary committee including additional profiles; 2) providing adequate training on gene therapy to healthcare professionals is a must to ensure quality of care; 3) the generation of a specific informed consent document and processes involving hepatology and psychology are essential, with the patient association playing a crucial role; 4) centres without prior practical experience in gene therapy must adapt specific areas to ensure correct preparation and administration; 5) short- and long-term patient follow-up should incorporate continuous monitoring of the patient's liver health and inclusion in registries for evaluation of outcomes.


This study was sponsored by CSL Behring.

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

Rare;3

https://doi.org/10.1016/j.rare.2025.100078

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)